Premium
Oxidized‐LDL and Atherosclerosis: Role of LOX‐1
Author(s) -
KITA TORU,
KUME NORIAKI,
YOKODE MASAYUKI,
ISHII KENJI,
ARAI HIDENORI,
HORIUCHI HISANORI,
MORIWAKI HIDEAKI,
MINAMI MANABU,
KATAOKA HIROHARU,
WAKATSUKI YOSHIO
Publication year - 2000
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2000.tb06304.x
Subject(s) - lysophosphatidylcholine , chemistry , hyperlipidemia , medicine , phospholipid , endocrinology , biochemistry , phosphatidylcholine , diabetes mellitus , membrane
A bstract : The accumulation of substantial numbers of monocyte/macrophages and activated T lymphocytes in focal areas of the arterial intima appears to be a hallmark of atherosclerosis. Our report demonstrated that lysophosphatidylcholine (lyso‐PC), a polar phospholipid component that is increased in atherosclerotic lipoproteins, such as oxidized LDL and remnant lipoproteins in diabetic and Type 3 hyperlipidemia, can upregulate adhesion molecules for monocytes and T lymphocytes, and growth factors, such as heparin‐binding epidermal growth factor‐like growth factor and PDGF A and B chains. Recently, we identified the novel receptor for oxidized LDL, named LOX‐1. We summarize the importance of the interaction between oxidized LDL and its receptor, LOX‐1, in terms of early stage atherogenesis.